AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
Go back to AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML| ALLIANCEBERNSTEIN HOLDING, L.P. (NYSE: AB) | Delayed: 36.31 +0.20 (0.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.11 | 52 Week High | $26.24 | |||
| Open | $35.76 | 52 Week Low | $16.11 | |||
| Day High | $36.37 | P/E | 21.36 | |||
| Day Low | $35.69 | EPS | $1.70 | |||
| Volume | 225,763 | |||||
